Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma.

被引：0
|
作者：
Coy, Shannon [1 ]
Lin, Jia-Ren [1 ]
Wang, Shu [1 ]
Stopka, Sylwia [2 ]
Rashid, Rumana [3 ]
Hwang, Jaeho [4 ]
Khadka, Prasidda [5 ]
Euskirchen, Philipp [6 ]
Bandopadhayay, Pratiti [5 ]
Wen, Patrick Y. [5 ]
Sorger, Peter K. [1 ]
Agar, Nathalie [2 ]
Ligon, Keith L. [7 ]
Touat, Mehdi [8 ]
Santagata, Sandro [2 ]
机构：
[1] Harvard Med Sch, Boston, MA 02115 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[4] Johns Hopkins Univ, Baltimore, MD USA
[5] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Charite Univ Med Berlin, Berlin, Germany
[7] Harvard Med Sch, Brigham & Womens Hosp, Dana, Boston, MA 02115 USA
[8] La Pitie Salpetriere Charles Foix Univ Hosp, Paris, France
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1816
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A nuclear localizing peptide that targets glioblastoma.
    Lewis, Calvin D.
    Singh, Abhay
    Kapoor, Vaishali
    Hallahan, Dennis E.
    CANCER RESEARCH, 2021, 81 (13)
  • [32] The role of plasma GFAP as a biomarker for glioblastoma.
    Husain, H.
    Savage, W.
    Everett, A.
    Ye, X.
    Blair, C.
    Romans, K. E.
    Bettegowda, C.
    Burger, P.
    Grossman, S. A.
    Holdhoff, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] COMPARISON OF GLIOBLASTOMA STEM LIKE CELLS AND GLIOBLASTOMA TISSUE USING GENE EXPRESSION AND PURINERGIC SIGNALING ANALYSES.
    Holland, H.
    Wallenborn, M.
    Kirsten, H.
    Xu, L. -X
    Richter, M.
    Ahnert, P.
    Krupp, W.
    Ulrich, H.
    Meixensberger, J.
    PURINERGIC SIGNALLING, 2018, 14 : S83 - S83
  • [34] Outcomes after hospitalization in patients with recurrent glioblastoma.
    Coecho Barata, Pedro Miguel
    Kamiya-Matsuoka, Carlos
    Lee-Kim, Soo
    Loghin, Monica Elena
    O'Brien, Barbara Jane
    Tremont-Lukats, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Phase 2 study of aldoxorubicin in relapsed glioblastoma.
    Groves, Morris D.
    Portnow, Jana
    Boulmay, Brian C.
    Chawla, Sant P.
    Dinh, Hillary
    Chawla, Shanta
    Wieland, Scott
    Levitt, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Age as a prognostic factor for treatment outcomes in glioblastoma.
    Braun, Kelly
    Mohapatra, Suryanarayan
    Choi, April
    Ahluwalia, Manmeet
    Jia, Xuefei
    NEUROLOGY, 2017, 88
  • [37] Targeting PIK3CB in glioblastoma.
    Fromherz, Marc R.
    Pridham, Kevin J.
    Sheng, Zhi
    CANCER RESEARCH, 2022, 82 (12)
  • [38] Phase II trial of dovitinib in recurrent glioblastoma.
    Ahluwalia, Manmeet Singh
    Papadantonakis, Nikolaos
    Venur, Vyshak Alva
    Schilero, Cathy
    Peereboom, David M.
    Stevens, Glen
    Rosenfeld, Steven
    Vogelbaum, Michael A.
    Elson, Paul
    Nixon, Andrew B.
    McCrae, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] A step-by-step protocol based on data mining to explore purinergic signaling in glioblastoma
    Bedeschi, Martina
    Agrawal, Ankita
    Adinolfi, Elena
    Tesei, Anna
    Vouret-Craviari, Valerie
    PURINERGIC SIGNALLING, 2025,
  • [40] Albumin levels and Prognostic Nutritional Index in glioblastoma.
    Bamashmos, Anas Saeed
    Barnett, Addison
    Ali, Assad
    Li, Honq
    Angelov, Lilyana
    Barnett, Gene H.
    Mohammadi, Alireza Mohammad
    Chao, Samuel T.
    Yu, Jennifer S.
    Murphy, Erin Sennett
    Suh, John H.
    Stevens, Glen
    Peereboom, David M.
    Ahluwalia, Manmeet Singh
    Wei, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345